Author

Charles Britten

Institution: Adc Therapeutics (Switzerland)

Observed institution: Adc Therapeutics (Switzerland)

ORCID: 0009-0006-0259-561X

Observed ORCID: 0009-0006-0259-561X

OpenAlex ID: A5129836486

From 3-Tier to adaptive immunogenicity testing strategies: recommendations from the European Bioanalysis Forum

2026 · Kyra J. Cowan, Rob Nelson, et al. · Bioanalysis · 5

An update on the European Bioanalysis Forum recommendation on singlicate analysis for ligand binding assays: biomarker and anti-drug-antibody assays

2026 · Michael Wright, Richard Hughes, et al. · Bioanalysis · 1

Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2026 · Asma Jabeen, Ben Leatherdale, et al. · Molecular Cancer Therapeutics

Works count: 3

Citation count: 6

H-index: 1

I10-index: